FindTrial
Sign In

Ketamine as an adjuvant for the treatment of first episode depression

Clinical utility of adjuvant ketamine in first episode depression- a double blind, placebo controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/04/042071
Enrollment
60
Registered
2022-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate Health Condition 2: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: Ketamine Adjuvant: This arm will receive three infusions of ketamine at 0.5mg/kg dosage on alternate days, in addition to SSRI (escitalopram 10 mg) Control Intervention1: Midazolam (act

Sponsors

Ahana Hospitals LLP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants willing to sign a written informed consent document; Participants must fulfill ICD criteria for Depressive episode , with the severity being moderate to severe Participants must be medically and neurologically healthy.

Exclusion criteria

Exclusion criteria: Those who have neurological disorders, severe medical illness, mental retardation and co-morbid psychiatric diagnoses Women who are pregnancy or breastfeeding Those who are allergic to ketamine

Design outcomes

Secondary

MeasureTime frame
Beck Scale for Suicidal Ideation (BSSI) to assess the level of suicidal ideationTimepoint: baseline, day 2 and day 14—

Primary

MeasureTime frame
Hamilton Depression rating scale (HAM-D) to assess severity of depressionTimepoint: baseline, day 2, day 14—

Countries

India

Contacts

Public ContactVikhram Ramasubramanian

Ahana hospitals, LLP

vikhram@ahanahospitals.in9443772233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026